BioMarin shares five-year Pompe disease drug data at muscle congress

October 2, 2026 11:00 AM

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) presented five-year Phase 3 open-label extension data for its two-drug combination Pombiliti (cipaglucosidase alfa-atga) and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found